All articles tagged with #cagrisema
Novo Nordisk presented real-world data indicating that patients switching from injectable obesity drugs to the new oral Wegovy pill continued losing weight. The analysis suggests the pill may offer convenience without sacrificing efficacy, potentially shifting patient preference away from weekly injections.
Novo Nordisk shares fell 8% after CEO Mike Doustdar's Capital Markets Day presentation failed to convince investors of a clear path to sustainable growth. Despite promising five multi-blockbusters by 2030 and a new consumer-focused segment, the market remains concerned about competition from Eli Lilly and the upcoming loss of patent exclusivity for semaglutide.
Novo Nordisk’s obesity drug CagriSema delivered slightly less weight loss than Lilly’s Zepbound in an 84-week phase 3 trial, raising questions about its market potential ahead of a late-2026 FDA decision and a possible 2027 launch. Novo defends the drug’s efficacy and points to additional trials (REDEFINE 11 and a higher-dose study) while analysts warn it may struggle to gain share from Zepbound, signaling potential reliance on future deals to bolster its pipeline.
Novo Nordisk’s next‑gen weight‑loss drug CagriSema failed to meet its primary endpoint in a late‑stage trial, delivering 23% average weight loss over 84 weeks versus 25.5% for Eli Lilly’s tirzepatide, prompting a sharp stock drop and renewed investor skepticism. The company plans a higher‑dose study and continues pursuing approval based on earlier data, while analysts noted the result as a setback for its obesity‑drug ambitions.
Novo Nordisk’s stock fell about 15% after its weight‑loss candidate CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide over 84 weeks (23% weight loss on CagriSema vs 25.5% for tirzepatide at 84 weeks). Lilly’s drug remains dominant in the market, and Novo is pursuing higher‑dose trials while facing competition, U.S. price pressure, and looming loss of exclusivity for Wegovy and Ozempic. The stock traded at its lowest since June 2021, and Lilly stock rose in premarket trading as Novo cautioned about slower growth in 2026.
Trial results for Eli Lilly’s retatrutide show about 28.7% weight loss after 68 weeks, higher than current meds, but with 12–18% dropout due to side effects and some participants reporting they were losing too much weight. Health experts caution about malnutrition and disordered eating, advocating dosing that is tailored to the patient and kept at the lowest effective level as obesity becomes a chronic disease; Novo Nordisk’s CagriSema uses flexible dosing to manage safety as full data from the retatrutide trial await publication.
Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.
Eli Lilly's stock rises as Novo Nordisk's new weight-loss drug trial results disappoint, with Lilly gaining investor confidence and analysts rating it a strong buy, while Novo Nordisk faces setbacks and stock decline.
Shares of Novo Nordisk fell up to 3.5% after trial data for its experimental obesity drug CagriSema raised investor concerns about its competitiveness against Eli Lilly, with questions about tolerability and market timing impacting investor confidence amid ongoing competition in the obesity market.
Novo Nordisk's obesity drug CagriSema, which combines Wegovy with a new medicine, showed promising weight loss results in studies, especially at lower doses, suggesting some patients respond well without needing the highest dose. The drug's safety profile is comparable to Wegovy, and the company plans to seek regulatory approval and conduct further studies, including head-to-head comparisons with competitors like Lilly's Zepbound.
Novo Nordisk's obesity drug CagriSema shows similar safety and efficacy to Eli Lilly's Zepbound, with initial weight loss of around 20% over 68 weeks, but the rate of weight loss plateaus, raising questions about its long-term effectiveness.